Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Human gut metagenome

ABSTRACT: Fecal microbiome analysis of patients with chronic obstructive pulmonary disease

PROVIDER: PRJNA562766 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other
	SRR10058635_1.fastq.gz	Fastqsanger.gz
	SRR10058635_2.fastq.gz	Fastqsanger.gz
	SRR10058636_1.fastq.gz	Fastqsanger.gz
	SRR10058636_2.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 305

Similar Datasets

trancription profiling by array of human pulmonary and circulating CD8 cells in COPD

Project description:Background: CD8 cells seem to play an important role in the pathogenesis of chronic obstructive pulmonary disease (COPD). However, relatively little is known about their phenotype and function. Aims: To define the transcriptome of pulmonary CD8 cells in COPD and compare to paired circulating CD8 cells and smoker control pulmonary CD8 cells. COPD was defined according to the Global initiative for chronic Obstructive Lung Disease guidelines. Severity of disease was defined according to the patients lung function. In particular the forced evpiratroy volume in 1 second (FEV1).

2013-08-01 | E-MTAB-1688 | biostudies-arrayexpress

Homo sapiens

Project description:Chronic obstructive pulmonary disease

| PRJNA85155 | ENA

Chronic Obstructive Pulmonary Disease (COPD) patient microbiome

Project description:Chronic Obstructive Pulmonary Disease (COPD) patient microbiome

| PRJEB46960 | ENA

Azithromycin effects on lung microbiome in COPD patient

Project description:Azithromycin (AZM) reduces pulmonary inflammation and exacerbations in chronic obstructive pulmonary disease patients with emphysema. The antimicrobial effects of AZM on the lung microbiome are not known and may contribute to its beneficial effects. Methods. Twenty smokers with emphysema were randomized to receive AZM 250 mg or placebo daily for 8 weeks. Bronchoalveolar lavage (BAL) was performed at baseline and after treatment. Measurements included: rDNA gene quantity and sequence. Results. Compared with placebo, AZM did not alter bacterial burden but reduced Î±-diversity, decreasing 11 low abundance taxa, none of which are classical pulmonary pathogens. Conclusions. AZM treatment the lung microbiome Randomized trial comparing azithromycin (AZM) treatment with placebo for eight weeks. Bronchoalveolar lavage (BAL) samples were obtained before and after treatment to explore the effects of AZM on microbiome, in the lower airways. 16S rRNA was quantified and sequenced (MiSeq) The amplicons from total 39 samples are barcoded and the barcode is provided in the metadata_complete.txt file.

2016-07-19 | E-GEOD-74396 | biostudies-arrayexpress

Azithromycin effects on lung microbiome in COPD patient

2016-07-19 | GSE74396 | GEO

Homo sapiens

Project description:Expression analysis of stable chronic obstructive pulmonary disease and acute exacerbation of chronic obstructive pulmonary disease

| PRJNA258183 | ENA

Transcription profiling of human diaphragm Chronic Obstructive Pulmonary Disease (COPD) patients vs. controls to study diaphragm muscle fast to slow adaptive transformation.

Project description:Diaphragm muscles in Chronic Obstructive Pulmonary Disease (COPD) patients undergo an adaptive fast to slow transformation that includes cellular adaptations. This project studies the signaling mechanisms responsible for this transformation.

2007-10-25 | E-GEOD-475 | biostudies-arrayexpress

Project description:Lung microbiome of chronic obstructive pulmonary disease patients in Tshwane, South Africa

| PRJNA683885 | ENA

Homo sapiens

Project description:Gene expression in chronic obstructive pulmonary disease (COPD) patients

| PRJNA310097 | ENA

lung metagenome

Project description:Lung microbiome dynamics in chronic obstructive pulmonary disease exacerbations

| PRJNA299077 | ENA